Načítá se...
Reading between the lines; understanding drug response in the post genomic era
Following the fanfare of initial, often dramatic, success with small molecule inhibitors in the treatment of defined genomic subgroups, it can be argued that the extension of targeted therapeutics to the majority of patients with solid cancers has stalled. Despite encouraging FDA approval rates, the...
Uloženo v:
| Vydáno v: | Mol Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528621/ https://ncbi.nlm.nih.gov/pubmed/24957465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.05.014 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|